Compare · EW vs ICUI
EW vs ICUI
Side-by-side comparison of Edwards Lifesciences Corporation (EW) and ICU Medical Inc. (ICUI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. EW focuses on Industrial Specialties, while ICUI focuses on Medical/Dental Instruments.
- EW is the larger of the two at $48.42B, about 16.3x ICUI ($2.97B).
- Over the past year, EW is up 11.7% and ICUI is down 13.2% - EW leads by 24.9 points.
- EW has been more active in the news (6 items in the past 4 weeks vs 1 for ICUI).
- EW has more recent analyst coverage (25 ratings vs 13 for ICUI).
- Company
- Edwards Lifesciences Corporation
- ICU Medical Inc.
- Price
- $83.99+0.54%
- $118.79-0.11%
- Market cap
- $48.42B
- $2.97B
- 1M return
- +3.30%
- -5.23%
- 1Y return
- +11.71%
- -13.22%
- Industry
- Industrial Specialties
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1992
- News (4w)
- 6
- 1
- Recent ratings
- 25
- 13
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
ICU Medical Inc.
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree connector products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoLock and ChemoClave closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, including sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation, such as sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. In addition, the company offers infusion pumps under the Plum 360 and LifeCare PCA brands; IV mediation safety software, including ICU Medical Mednet, an enterprise medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; and related professional services. Further, it provides critical care products comprising Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company sells its products to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.
Latest EW
- Edwards Lifesciences to Present at the BofA Securities 2026 Health Care Conference
- Edwards Lifesciences Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Edwards Lifesciences Reports First Quarter Results
- Edwards Lifesciences to Host Earnings Conference Call on April 23, 2026
- SEC Form 4 filed by Ullem Scott B.
- SEC Form 4 filed by Lippis Daniel J.
- SEC Form 4 filed by Bobo Donald E Jr
- Edwards Lifesciences upgraded by Wolfe Research with a new price target
- Two Year Data on Edwards Lifesciences' EVOQUE System Continue to Demonstrate Significant and Sustained Patient Benefits
- Amendment: SEC Form SCHEDULE 13G/A filed by Edwards Lifesciences Corporation
Latest ICUI
- ICU Medical Announces Time of First Quarter 2026 Earnings Conference Call
- SEC Form DEFA14A filed by ICU Medical Inc.
- SEC Form DEF 14A filed by ICU Medical Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by ICU Medical Inc.
- SEC Form 4 filed by Abbey Donald
- SEC Form PRE 14A filed by ICU Medical Inc.
- Chief Operating Officer Voigtlander Christian B. converted options into 14,648 shares and covered exercise/tax liability with 8,096 shares, increasing direct ownership by 16% to 46,306 units (SEC Form 4)
- VP, GM-Infusion Capital Woolson Daniel covered exercise/tax liability with 1,295 shares and converted options into 2,924 shares, increasing direct ownership by 7% to 24,602 units (SEC Form 4)
- Chief Information Officer Sousa Ben converted options into 1,300 shares and covered exercise/tax liability with 718 shares, increasing direct ownership by 12% to 5,326 units (SEC Form 4)
- VP, General Counsel Sanzone Virginia Ruth converted options into 7,324 shares and covered exercise/tax liability with 4,047 shares, increasing direct ownership by 18% to 21,907 units (SEC Form 4)